Rising Incidence of Cancer and Heart Diseases Drives the Angiogenesis Inhibitors and Stimulators Market, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Angiogenesis Inhibitors and Stimulators markets. The global market for Angiogenesis Inhibitors and Stimulators is forecast to reach US$68 billion by the year 2017, driven by the rising incidence of cancer and heart diseases, increasing aging population worldwide, and unmet needs in present oncology therapeutic area. Additionally, growing adoption of approved Anti-Angiogenic Drugs as well as robust pipeline of efficacious new drugs across diverse cancer indications are expected to stimulate future growth in the Angiogenesis Inhibitors market.

Angiogenesis Inhibitors and Stimulators: A Global Strategic Business Report

Follow us on LinkedInAngiogenesis plays a crucial role in the growth and regeneration of tissues. Research and development activities are underway to gain an extensive insight into this arena. However, between angiogenic inhibitors and angiogenic stimulators, the market for angiogenic inhibitors stands apart for its potential and promising applications in addressing diseases, such as cancer, dermatological, and inflammatory conditions. Angiogenic inhibitors are gaining large-scale acceptance, mainly contributed by the growing confidence for their targeted application against serious diseases, such as cancer. Angiogenic inhibitors also find application in the arena of cardiology and rheumatology. On the other hand, Angiogenic stimulators play a crucial role in cases requiring extensive supply of blood. They are the ideal source of blood supply during wound healing and certain cardiovascular diseases.

Research and development of novel angiogenic drugs is highest in the field of cancer treatment. Angiogenesis inhibition affects the survival of tumor cells and this offers a huge scope for the development of novel drugs targeting angiogenic receptors. Subsequently, the global pharmaceutical market, during the past decade, witnessed the introduction of several anti-angiogenesis drugs that aid in arresting tumor growth in various types of cancers. Additionally, several more compounds are in various stages of clinical development. Industry participants are focusing on the development of drugs that target several signaling and regulatory molecules that include growth factors, such as Vascular Endothelial Growth Factors (VEGF), Platelet-Derived Growth Factors (PDGF), and Fibroblast Growth Factors (FGF), transcription factors, receptor tyrosine kinases, among others. Continuing robust growth of marketed drugs, and a promising pipeline of drugs vying to demonstrate superior efficacy in various cancers, bode substantial growth in the market in the following years.

The US represents the single largest regional market for angiogenesis inhibitors and stimulators worldwide, as stated by the new market research report on Angiogenesis Inhibitors and Stimulators. Europe trails behind the US market. Avastin, marketed by Roche, Genentech and Chugai worldwide, is the largest selling Angiogenic Inhibitor drug worldwide. Since its first approval in 2004, Avastin has witnessed significant growth over the recent years. However, recently, Avastin’s approval by the FDA for breast cancer treatment was revoked, as studies revealed that delay of breast cancer progression using Avastin combined with chemotherapies is comparatively no better than any other therapy administered singly. Also, C-08, a study of Avastin’s use in recurrence of colon cancer post surgery, demonstrated the inefficiency of the drug. Nevertheless, the drug is being studied for various other indications, few of which have demonstrated positive outcomes. The potential use of Avastin in treating other type of tumors in combination with various chemotherapy regimens as well as targeted therapies, such as Apomab, Dulanermin, Tarceva, and Herceptin, among others is currently being explored.

Several drugs with anti-angiogenic activities have subsequently forayed into the market. Tyrosine kinase inhibitors or RTK inhibitors such as Novartis’ Gleevec, OSI Pharmaceuticals’s Tarceva, and ImClone’s Erbitux were the other key drugs that entered into the market, subsequent to Avastin. Most of these drugs act by interfering signaling between growth factors and receptors known for assisting tumor growth, thereby leading to indirect inhibition of angiogenesis.

Major players profiled in the report include Abbott Laboratories, Adnexus Therapeutics Inc., Æterna Zentaris Inc., Amgen Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc., Bayer HealthCare AG, Callisto Pharmaceuticals Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, EntreMed Inc., GlaxoSmithKline Plc., Merck, Novartis, OSI Pharmaceuticals, Pfizer, Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co. Ltd., Silence Therapeutics, ThromboGenics Limited, among others.

The research report titled “Angiogenesis Inhibitors and Stimulators: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the angiogenesis inhibitors and stimulators market, current market trends, key growth drivers, overview of major drugs, insight into the current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for angiogenesis inhibitors and stimulators market for the years 2009 through 2017 for the following geographic markets - US, Europe, and Rest of World; and by the following market segments – Angiogenesis Inhibitors and Angiogenesis Stimulators. Also, a six-year (2003-2008) historic analysis is provided for an additional perspective.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website